🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to announce the publication of #Genomic Landscape in #pcsm in #LATAM Thanks JCO Global Oncology Maite Bourlon Ray Manneh Kopp Bere Freile Federico Cayol Rodrigo Sanchez Roger José M Peñaloza Ernesto Maturana Carolina Passarella Laura Bernal Vaca Patricia Rioja Silvia Neciosup ascopubs.org/doi/10.1200/GO…

Germline EGFR T790M occurs more often in Whites, with a distinct radiological pattern and family history of lung cancer without smoking history. Kelsey Pan, MD, MPH MD Anderson Cancer Center Eric K. Singhi, MD Journal of Thoracic Oncology jto.org/article/S1556-…

Honored to be part of this multicentric translational collaboration! Congrats Florencia Cascardo rdcu.be/dXXpu Diego Enrico Pablo Mando Fundación IBYME

Proud to be elected president of the Argentina Association of Clinical Oncology #AAOC Orgulloss de haber sido electo presidente se la Asociacion Argentina de Oncologia Clinica #AAOC

El nuevo numero de la revista Oncologia Clinica de la Asociación Argentina de Oncología Clínica (AAOC) ya esta disponible Manglio Rizzo Federico Waisberg Greta Catani luis basbus Maria Illia Dana Narvaez, MD Florencia Sarrú Diego Enrico

Reserva las fechas para el 4.º Congreso Iberoamericano: Lo Mejor en Cáncer de Pulmón 2024, los días 26, 27 y 28 de febrero del 2025 🗓️, formato Virtual, completamente gratuito. ¡No te lo puedes perder! #CLICaP #Congress #Cáncerdepulmón #Oncología #Iberoamérica🫁

Contacto: [email protected]

👏 nueva sub comisión Asociación Argentina de Oncología Clínica (AAOC) ..... siempre innovando #SaludDigital 🤳 #IA 🖥️ FLoscoMD Andrea Marchioni Enrique Diaz Canton Diego Enrico José Máximo Barros, MD 🇦🇷 Pablo CASTRO PEÑA Pablo Companys Claudio Martin

⏰NOW OUT‼️#ELCC25 🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS 🎙️Prof. James Yang 🎯OS HR 0.75 (95%CI: 0.61-0.92) 🎯Anticipated to prolong mOS by at least 1⃣2⃣mo ✅NCT04487080 #LCSM OncoAlert ESMO - Eur. Oncology IASLC

Morning > Afternoon for IO? Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat). Given IO’s long half-life, maybe only the timing of the first dose matters. #ASCO2025

#NEJM. Thank you to IAF Team. ⁦Diego Enrico⁩ ⁦carmen pupareli⁩ ⁦Florencia Tsou⁩ @Delfinaperalta and Research Team INCOAS

Cada vez es más compleja la atención de los pacientes con cáncer de pulmón. Los esperamos para comenzar con los 🫁 ECHO Torax 📍Modalidad virtual 🗓 24/06 🕜 14 a 15 hs #comitedetorax #enfoquemultidisciplinario #cancerdepulmon #IAF #projectECHO

Today, we lost one of the greatest oncologists in history, Argentine Prof. Esteban Cvitkovic, developer of cisplatin and numerous pivotal drugs in oncology. He was a mentor and huge friend to countless oncologists and researchers worldwide. We will never forget you, Esteban.

Lung cancer survival more than doubles from 2000-2020 due to the collective efforts of precision medicine, immunotherapy, & early detection - 5015pts w lung adenocarcinoma🇫🇷 - mOS 8.5m (2000) v 20.7m (2020) ⁦OncoAlert⁩ #LCSM evidence.nejm.org/doi/full/10.10…

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

Están todos invitados a escuchar sobre las últimas novedades en cáncer de pulmón! Los esperamos!